Immune thrombocytopenia (ITP) is an autoantibody-mediated bleeding disorder with both accelerated platelet destruction and impaired platelet production. We and others have described impaired regulatory CD4 + CD25 hi T cells (Treg) numbers and/or suppressive function in ITP patients. Clinical trials using thrombopoietic agents to stimulate platelet production have shown favorable outcomes in ITP patients, but information on the immunologic responses of treated patients are lacking. We studied the immunological profile of chronic ITP patients before (n=10) and during treatment with thrombopoietin receptor (TPO-R) agonists (n=9). Treg activity, as measured by suppression of proliferation of autologous CD4 + CD25 -cells, was improved in patients on treatment (p<0.05) and the improvement correlated with reduction in IL-2-producing CD4 + cells, consistent with dampening of immune responses. There was a concomitant increase in total circulating TGF-β1 levels (p=0.002) in patients on treatment and the levels of TGF-β1 correlated with the degree of improvement in platelet counts (r=0.8, p=0.0002). This suggests that platelets in patients on TPO-R treatment may play a role in improving Treg function, either directly or indirectly by enhanced release of TGF-β1 as a result of greater platelet turnover. In conclusion, our findings suggest that thrombopoietic agents in patients with ITP have profound effects to restore immune tolerance.
Introduction
Immune thrombocytopenia (ITP) is a bleeding disorder due to low platelet counts with an incidence of 2 and 12 per 100,000 adults and children, respectively per year and a mortality rate of 1-3% per year in severely affected cases. 1, 2 Autoreactive antibodies to platelet antigens, mainly the platelet glycoprotein IIb/IIIa complex, are considered responsible for accelerated destruction of platelets by the reticuloendothelial system and also reduced platelet production. 3 While healthy individuals harbor platelet-specific autoreactive T cells that are tolerized in the periphery, 4 patients with ITP possess activated platelet-autoreactive T cells with increasing cytokine imbalance toward IL-2 and IFN-γ [5] [6] [7] [8] [9] especially in patients with chronic ITP with some also reporting higher levels of circulating pro-inflammatory cytokines tumour-necrosis factor (TNF-α) 10 and soluble CD40 ligand (sCD40L). 11 These data are consistent with loss of peripheral tolerance and an inflammatory phenotype in chronic ITP patients.
CD4
+ regulatory T cells (Tregs) play a critical role in maintenance of peripheral tolerance by both directly and indirectly suppressing the activation and proliferation of many cell types,
including T cells, B cells, dendritic cells, natural killer (NK) cells, and NKT cells in vivo and/or
in vitro. 12 Because of their ability to control homeostasis and immunopathology, 13 the level of
Tregs and their function are among the most informative criteria of a patient's immune status.
Tregs are characterized by high expression of the CD25 molecule (the IL-2 receptor α -chain) and expression of the transcription factor Foxp3, and make up 5-10% of the normal peripheral CD4 + T cell population. 14;15 As with a number of other autoimmune diseases, recent studies in patients with ITP have shown reduced levels of Foxp3 mRNA 16 and protein 17 in circulating mononuclear cells and abnormal Treg function in spleen biopsies. 18 We recently showed that circulating Treg suppressive activity was reduced in patients with chronic ITP and that the defect was intrinsic to Tregs rather than a result of effector T cells resisting suppression. 19 These studies indicate that deficiency in generation and/or defective functions of Tregs may contribute to the loss of immunologic self-tolerance and pathogenesis in patients with ITP. In particular, failure to maintain immune suppression by Tregs may explain the reported platelet autoantigenspecific T cell proliferative responses and the proinflammatory phenotype in ITP patients.
Interestingly, chronic ITP patients treated with rituximab whose platelet counts improve show restored numbers of Tregs as well as restored regulatory activity as determined by in vitro cell 21 Altogether, the data are consistent with the immunomodulatory nature of such treatment modalities in the setting of chronic ITP.
More recently, a number of thrombopoietic agents have been developed and shown to be highly effective in the treatment of ITP. 22 These agents include a thrombopoietic mimetic containing the thrombopoietin receptor (TPO-R)-activating peptides attached to the Fc portion of IgG (Nplate or Romiplostim or AMG 531) given as weekly subcutaneous injections, and small molecule TPO-R agonists administered as daily oral tablets (eltrombopag or Promacta; AKR-501; and LGD4665).
They increase thrombopoiesis by activating TPO receptors (TPO-R), thereby increasing the production of mature megakaryocytes and platelets. 23 Romiplostim and eltrombopag have completed phase I-III clinical trials and over 70% of patients had achieved "safe" levels of platelet counts that prevent bleeding (≥50 × 10 9 /L) with favorable outcomes with respect to safety and tolerability with both drugs. [24] [25] [26] [27] [28] AKR-501 has completed a phase I trial, demonstrating an increase of more than 50% over the baseline platelet count in 5 out of 6 healthy volunteers tested 29 and additional clinical trials in patients with chronic ITP are underway. No information is currently available on the immune responses of patients treated with any of these drugs as it relates to prognosis and response to treatment.
In this study, we analyzed the immunological profiles of a cohort of patients before treatment and in patients who had been on treatment with thrombopoietic agents. Surprisingly, we found an improvement in the Treg activity of patients on treatment and a decrease in their proinflammatory sCD40L with a concomitant increase in their circulatory TGF-β1 that correlated with increase in platelet counts. These data suggest that thrombopoietic agents possess immunomodulatory activity as indicated by the improved peripheral Treg function in patients on treatment and an accompanying decrease in inflammatory state. In addition, the data raises the interesting possibility that the increase in platelet counts may play a role in mediating the increase in Treg function in patients on treatment.
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Materials and Methods

Patient population
All the studies were approved by the institutional Review Boards of the Weill Medical College of Cornell University and of the New York Blood Center. Peripheral blood was obtained from 17 patients (all Caucasian) with chronic ITP study ( Table 1 ) and 9 healthy normal healthy volunteers as controls upon informed consent in accordance with the Declaration of Helsinki. In two cases (patient #9 and patient #10), we were able to sample blood from the same patient before they started treatment with thrombopoietic agents ("pre-treatment") and after 4 months on treatment ( Table 1 ). The "pre-treatment" group (total n=10, including patients #9 and #10) consisted of 8 females and 2 males with median age 58.5 years (range 17-70) who had completed their previous treatment (non-thrombopoietic agents) at least 2 weeks prior their study visit (Table 1 ). The on-treatment group (total n=9, including patients #9 and #10) consisted of 8 females and 1 male with median age 54 years (range 46-80) who had been on treatment with thrombopoietic agents (with romiplostim, n=4, eltrombopag, n=1 or an investigational thrombopoietic agent AKR-501, n=4) for at least 4 months at the time of the visit (Table 1) .
Proliferation/Treg cell suppression assay
To purify Tregs, CD4 + cells were first enriched by positive selection (Miltenyi Biotech, Auburn, 
Surface and Foxp3 staining
To determine the frequency of Tregs, freshly obtained whole blood (150μl/tube) was first incubated with CD4-PerCP and CD25-APC (BD Biosciences, San Jose, CA) prior to staining for Cells were analyzed by BD FACSCanto using Diva software (BD, Franklin Lakes, NJ).
Cytokine detection
For detection of circulatory TGF-β1 and sCD40L levels, platelet-poor plasma was first prepared following a modified protocol by Lee et al. 30 Briefly 
Statistical analysis
Statistical analyses were performed using Mann-Whitney U test (platelet counts, Treg frequency, cytokine measurements), non-parametric Spearman correlation (all correlation studies), and 2-way ANOVA for repeated measurements (Treg assay). Differences were considered significant at p < 0.05. 
Results
Treg activity improves in patients on treatment with thrombopoietic agents
To determine whether Treg frequency/activity is affected following treatment with thrombopoietic agents, we compared the peripheral Treg compartment of a group of chronic ITP patients with platelet counts of below 40 x10 9 /L before they went on treatment (n=10) with that of a second group (n=9) who had been on treatment with thrombopoietic agents for more than 4 months ( Table 1 ). All but one patient (#10) in the "on treatment" group was being treated exclusively for ITP with thrombopoietic agents. The "on treatment" group showed an improved platelet counts (Fig. 1, p=0 .002). We found no statistically significant differences in the Treg frequencies (Foxp3 + CD25 hi in the CD4 + population 19 ) of patients before treatment and those on treatment (2.7% ± 0.4% vs 3.1% ±0.6 % all p values >0.1, Fig.2 ) and similarly no differences in the levels of Foxp3 expression in the CD4 + CD25 hi population (data not shown).
We next compared the functional activity of CD4 + CD25 hi subset in patients before and on treatment by purifying and testing them ex vivo using a mixed lymphocyte proliferation assay. 53% ±7% for pre-treatment group and at 1:4, 51% ±6% vs. 35% ±7% respectively, overall p=0.045), but was lower than those of healthy volunteer controls (at 1:1 ratio, 70% ±2% and at 1:4 ratio, 50% ±5%). To determine whether the improved Treg activity correlated with altered helper T cell cytokine secretion pattern, we analyzed the intracellular cytokine expression in stimulated sorted CD4 + population. It has been reported that PBMCs from a majority of patients with chronic ITP when stimulated secrete higher levels of IL-2, possibly as a result of continuously activated autoimmune responses. 5 We found a significant negative correlation between levels of IL-2 expression in stimulated, sorted CD4 + T cells and Treg suppressive (Fig 4, r=-0 .47, p=0.04), suggesting that improved Treg activity is linked to dampening of immune responses, in particular related to IL-2.
Circulating plasma levels of TGF-β1 and sCD40L
TGF-β1 is primarily considered an anti-inflammatory cytokine, promoting Treg development and function, and inhibiting Th1 and Th2 development as well as B cell proliferation and antibody production. 33 A number of studies have indicated that ITP patients have low circulating TGF-β1 levels which increase as platelet counts improve following various treatments. [34] [35] [36] We therefore measured total circulating TGF-β1 in some of our patient cohort using the platelet poor fraction of the plasma to avoid potential in vitro platelet activation/degranulation. We found that circulating TGF-β1 levels strongly correlated with platelet counts in our patient cohort (Fig. 5,   r=0 .8, p=0.0002) with higher levels of TGF-β1 in the patient group on treatment compared to the pre-treatment group (Fig. 6 , 2211pg/ml ± 345 pg/ml vs 1083 pg/ml ± 127 pg/ml, p=0.02).
Concurrently, we also tested levels of circulating sCD40L, a proinflammatory cytokine in the platelet poor plasma fraction in our patient cohort and found a decrease in the levels in patients on treatment (0.88±0.13 ng/ml vs 0.53±0.05 ng/ml, p=0.02) as has previously been reported in treated patients with ITP.
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Discussion
We have found in a small cross-sectional study improved in vitro Treg function in chronic ITP patients who have been on thrombopoietic agents, suggesting for the first time that these agents may possess immunomodulatory activity in addition to their profound effects on platelet counts.
The increase in Treg suppressive activity correlated with a reduction in effector T helper functions as manifested by a negative association between Treg activity and the frequency of IL-2 expressing CD4 + T cells. Moreover, patients on treatment had increased circulating TGF-β1 levels but decreased sCD40L levels, both suggesting a reduction in the overall inflammatory state. Whether the increase in Treg activity in patients on treatment is a cause or consequence of decrease in the inflammatory state remains to be determined by future longitudinal studies.
Because TPO receptor expression is largely restricted to the megakaryocytic compartment, 37 it is unlikely that the thrombopoietic agents directly interact with the Tregs to improve their activity.
Instead, our hypothesis is that the effect of thrombopoietic agents on Tregs is mediated indirectly
by TGF-β1 released by platelets and/or megakaryocytes. In support of this latter possibility, we found a strong association between platelet counts and circulating TGF-β1 levels. Platelets are a rich source of TGF-β1, containing 40-100 times more than other cell types 38 and they release TGF-β1 following activation/degranulation. 38 The cause of elevated TGF-β1 levels in patients on thrombopoietic agents is not known, but an artifactual platelet activation during venipuncture in only in one patient group, but not healthy controls who have equal or higher platelet counts seems unlikely. Moreover, we find decreased levels of sCD40L, known to be abundant in platelets and released following platelet activation 39 in the same plasma samples in patients on TPO-R agonists, further arguing against an artifactual platelet activation during venipuncture.
These data further support a previous report 40 that platelets are not activated in patients on thrombopoietic agents. The reason why circulatory sCD40L, which are mostly platelet-derived, are higher in patients in our pre-treatment group as well as in patients with low platelet counts 11 is not known, but it may be that sCD40L is derived from a non-platelet source (eg. T cells) 41 in patients who have low platelet counts. In addition, the mechanisms that cause the release of sCD40L, but not TGF-β1 in patients with low platelet counts remain to be fully determined, but it is possible that these cytokines may belong to different platelet granule sorting/release pathways. 42 For personal use only. on October 24, 2017. by guest www.bloodjournal.org From TGF-β1 may also be released by (increased numbers of) megakayocytes. 43 It is possible that with increased platelet turnover in patients on thrombopoietic agents, there is increased platelet clearance with concomitant release of TGF-β1. Interestingly, ITP patients with improved platelet counts following treatment with immunosuppressive drugs, high dose dexamethasone, IVIG or splenectomy were also shown to have increased TGF-β1 levels, [34] [35] [36] although direct correlation studies between TGF-β1 levels and platelet counts were not reported. These latter treatments when effective are thought to prevent or minimize platelet destruction which is in contrast to the effect of thrombopoietic agents that increase platelet turnover. Future studies are needed to determine the mechanisms by which TGF-β1 levels are increased in patients on thrombopoietic agents and how these mechanisms may differ, if at all, in patients, who are on treatments that interfere with platelet destruction. Alternatively, it may also be that as platelet counts improve, there is altered processing/presentation of platelet antigens by the antigen presenting cells, resulting in Treg normalization.
TGF-β1 can induce Foxp3-negative T cells and convert them to Foxp3 + Tregs. 44 Although we did not find any correlation between TGF-β1 levels and the frequency of med and CD4 + CD25 neg populations, whose regulatory role remains questionable. 45, 46 Longitudinal studies are needed to determine whether TGF-β1 levels correlate with induction of TGF-β1 has also been shown to be essential for maintenance of Treg functions. 44 Specifically, CD4 + CD25 + Treg from transgenic mice overexpressing a truncated version of the TGF-β type II receptor that acts as a dominant negative mutant receptor had decreased in vivo suppressive capacity, indicating that TGF-β1 signaling is essential to maintain Treg suppressive function. 47 We were unable to find a direct correlation between Treg suppressive activity and TGF-β1 levels.
However, in 2 cases (patients #9 and #10, Table 1 ) we were able to perform analysis before and on treatment on the same patients. With patient #9 whose platelet count was 26 x10 9 /L before treatment and increased to 66 x10 9 /L on the drug, we found a 20% increase in peripheral TGF-β1 levels and a concomitant 20% improvement in Treg activity while in patient #10 with platelet counts of 36 x10 9 /L prior to treatment to 290 x10 9 /L on treatment, TGF-β1 levels and Treg activity both increased by 30%. As our study had a cross sectional design, longer term longitudinal studies are required to validate the clinical significance of the elevation of Treg activity observed in patients on treatment with thrombopoietic agents and to further explore the role of platelets and its association with Tregs in ITP. The recent development of a mouse model of ITP 48 is likely to be helpful in addressing some of these questions.
It is our prediction that antigen-specific Treg responses are increased in patients on treatment in parallel to polyclonal Treg activity, but these studies have not yet been performed. In the study by Kuter et al., 25 only about 10% of the ITP patients treated with a thrombopoietic agent for 6 months did not relapse in the 12 weeks of follow up. What fraction of patients will relapse when longer ie years instead of months of therapy is discontinued remains unexplored and needs further study. Of note, 5/9 patients in the on treatment group had been taking the thrombopoietic agents for ≥ 1 year (Table 1) . It is possible that because functional Tregs are already induced in these patients, treatment regimens optimized to fully restore platelet counts will gradually lead to establishment of stable Treg populations to achieve long term immune tolerance.
In summary, we have found an improved in vitro Treg activity with a concomitant decrease in effector T helper functions in patients on treatment with TPO-R agonists. Furthermore, patients on treatment had increased circulating TGF-β1 levels but decreased sCD40L levels, indicating that a reduction in the overall inflammatory state. While the data needs to be validated in longitudinal study, our current study suggests that thrombopoietic agents which have already been shown to be highly effective in the treatment of ITP, may also be pro-tolerogenic too. during treatment with thrombopoietic agents. ). All patients "on treatment" were considered responsive to the thrombopoietic agents, where responsiveness is defined as increasing the platelet count from >30 x10 9 /L before starting treatment to a count usually over 50 x10 9 /L while on treatment. The platelet counts indicated in the Table correspond to the patients' counts on the day that their blood was analyzed for this study. Thus, although patient #12 had a platelet count of 31 x10 9 /L when we collected blood for our analysis, the common count for this patient while on treatment was over 50 x10 9 /L. Out of a total of 17 patients, 3 patients were receiving daily low (less than 3mg) dose immunosuppressive prednisone regimen and one on higher (60mg)
dose at the time of their visit and all except one (patient #10) was in the pre-treatment group. Platelet counts are shown for the same day that blood was sampled for immunological analysis. hi in patients before treatment was 53% ±7%, but was higher in patients on treatment (63% ±4%). Similarly, at 1:4, the pre-treatment group had a lower suppressive activity (35% ±7%) compared to on treatment group of 51% ±6% (overall p=0.045). For comparison, the healthy volunteer controls suppressive activity at 1:1 ratio (70% ±2%) and at 1:4 ratio (50% ±5%) is also indicated. The raw proliferation data is shown as a supplementary figure 2.
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Correlative analysis indicated a strong positive association between the patients platelet counts and TGF-β1 levels (r=0.8, p=0.0002). For personal use only. on October 24, 2017. by guest www.bloodjournal.org From
